Literature DB >> 2984538

Cannabinoid inhibition of adenylate cyclase. Biochemistry of the response in neuroblastoma cell membranes.

A C Howlett.   

Abstract

The inhibition of adenylate cyclase activity by cannabimimetic compounds in a membrane fraction from cultured neuroblastoma cells has been examined. The inhibition was shown to be concentration-dependent over a nanomolar range for both delta 9-tetrahydrocannabinol and its synthetic analog, desacetyllevonantradol. Inhibition was rapid and reversible. The cannabimimetic compounds caused a decrease in Vmax of the enzyme, with no alteration in the Km for substrate. The effects of these compounds were related to the ability of the enzyme to be regulated by divalent cations and guanine nucleotides. The inhibition was greatest at micromolar Mg2+ or Mn2+ concentrations and was abolished at less than 1 mM MnCl2. In the hormone-stimulated state, the enzyme appeared to be regulated by one Mg2+ site. The addition of cannabimimetic or muscarinic cholinergic agents transformed the enzyme into one in which more complex regulation by divalent cations was observed. Half-maximal inhibition of adenylate cyclase was observed at 800 nM GTP for both cannabimimetic and muscarinic cholinergic agents. The substitution for GTP of a nonhydrolyzable analog resulted in activation of the enzyme and failure to respond to either class of inhibitory agents. If the Mg2+ concentration was reduced and exposure to the GTP analog was of short duration, inhibition by both cannabimimetic and muscarinic agents could be observed in the presence of forskolin. This study points to the similarities between the enzyme inhibition by cannabimimetic compounds and by muscarinic cholinergic compounds. It is inferred that the cannabimimetic compounds must act via regulatory mechanisms similar to those operating for receptor-mediated inhibition of adenylate cyclase.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2984538

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  50 in total

1.  Ultrastructural localization of the CB1 cannabinoid receptor in mu-opioid receptor patches of the rat Caudate putamen nucleus.

Authors:  J J Rodriguez; K Mackie; V M Pickel
Journal:  J Neurosci       Date:  2001-02-01       Impact factor: 6.167

2.  Structural domains of the CB1 cannabinoid receptor that contribute to constitutive activity and G-protein sequestration.

Authors:  J Nie; D L Lewis
Journal:  J Neurosci       Date:  2001-11-15       Impact factor: 6.167

3.  Novel 1',1'-chain substituted hexahydrocannabinols: 9β-hydroxy-3-(1-hexyl-cyclobut-1-yl)-hexahydrocannabinol (AM2389) a highly potent cannabinoid receptor 1 (CB1) agonist.

Authors:  Spyros P Nikas; Shakiru O Alapafuja; Ioannis Papanastasiou; Carol A Paronis; Vidyanand G Shukla; Demetris P Papahatjis; Anna L Bowman; Aneetha Halikhedkar; Xiuwen Han; Alexandros Makriyannis
Journal:  J Med Chem       Date:  2010-10-14       Impact factor: 7.446

4.  Nonclassical and endogenous cannabinoids: effects on the ordering of brain membranes.

Authors:  A S Bloom; W S Edgemond; J C Moldvan
Journal:  Neurochem Res       Date:  1997-05       Impact factor: 3.996

Review 5.  [Cannabinoids--signal transduction and mode of action].

Authors:  R Rukwied; B Gauter; M Schley; C Konrad
Journal:  Schmerz       Date:  2005-11       Impact factor: 1.107

6.  The Central Role of Glia in Pathological Pain and the Potential of Targeting the Cannabinoid 2 Receptor for Pain Relief.

Authors:  Jenny L Wilkerson; Erin D Milligan
Journal:  ISRN Anesthesiol       Date:  2011

Review 7.  Emerging role of the cannabinoid receptor CB2 in immune regulation: therapeutic prospects for neuroinflammation.

Authors:  Guy A Cabral; LaToya Griffin-Thomas
Journal:  Expert Rev Mol Med       Date:  2009-01-20       Impact factor: 5.600

Review 8.  Cannabinoids as therapeutic agents for ablating neuroinflammatory disease.

Authors:  G A Cabral; L Griffin-Thomas
Journal:  Endocr Metab Immune Disord Drug Targets       Date:  2008-09       Impact factor: 2.895

Review 9.  Activation of G-proteins in brain by endogenous and exogenous cannabinoids.

Authors:  Steven R Childers
Journal:  AAPS J       Date:  2006-03-10       Impact factor: 4.009

10.  Cannabinoid ligand-receptor signaling in the mouse uterus.

Authors:  S K Das; B C Paria; I Chakraborty; S K Dey
Journal:  Proc Natl Acad Sci U S A       Date:  1995-05-09       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.